Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Serina Therapeutics Inc SER

Healthcare Biotechnology
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:SER)

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

GlobeNewswire February 12, 2025

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

GlobeNewswire February 3, 2025

Serina Therapeutics Announces Sale of UniverXome Subsidiary

GlobeNewswire January 15, 2025

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

GlobeNewswire January 14, 2025

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

GlobeNewswire December 16, 2024

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

GlobeNewswire December 11, 2024

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

GlobeNewswire December 2, 2024

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire November 12, 2024

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

GlobeNewswire November 11, 2024
View More News ››

Opinion & Analysis (NYSEAM:SER)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:SER)

(SER) Technical Data

JUST IN: $SER (SER) Technical Data2024-12-11 04:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method...
whytestocks - December 11, 2024
View more Bullboard ››

Lode Gold Resources Inc.

Lode Gold Resources Inc.

Lode Gold Resources Inc. is a Canadian exploration and development company with grassroots and advanced exploration ...
View More »